`Filed: November 21, 2023
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`SUN PHARMACEUTICAL INDUSTRIES LTD.
`and
`SUN PHARMACEUTICAL INDUSTRIES, INC.,
`Petitioners,
`v.
`
`NOVO NORDISK A/S,
`Patent Owner.
`
`U.S. Patent No. 10,335,462 to Jensen
`Issue Date: July 2, 2019
`Title: Use of Long-Acting GLP-1 Peptides
`
`
`
`
`
`Inter Partes Review No. IPR2024-00107
`
`
`
`
`
`PETITIONER’S UPDATED MANDATORY NOTICE
`UNDER 37 C.F.R. 42.8(a)(3)
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting in
`
`a representative capacity for Sun Pharmaceutical Industries Ltd. and Sun
`
`Pharmaceutical Industries Inc. (collectively “Petitioner”), hereby submits the
`
`following mandatory change-of-information notices in connection with the petition
`
`for inter partes review of U.S. Patent No. 10,335,462, Case IPR2024-00107, to
`
`remove Mr. Christopher W. West as backup counsel for Petitioner.
`
`A. Real Parties-In-Interest
`In accordance with 37 C.F.R. § 42.8(b)(1), the real parties-in-interest for
`
`Petitioner are Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries
`
`Inc.
`
`B. Related Matters
`In accordance with 37 C.F.R. § 42.8(b)(2), Petitioner is not aware of any
`
`reexamination certificates or pending prosecution concerning the ’462 patent.
`
`Petitioner is a defendant in the following consolidated litigation involving the ’462
`
`patent:
`
`• Novo Nordisk Inc. and Novo Nordisk A/S v. Sun Pharmaceutical
`Industries Ltd. and Sun Pharmaceutical Industries, Inc., No. 1:22-cv-
`00296 (D. Del.) (transferred to MDL on August 5, 2022);
`• In re Ozempic (Semaglutide) Patent Litigation, No. 22-md-3038-CFC
`(D. Del.); and
`• Novo Nordisk Inc. and Novo Nordisk A/S v. Rio Biopharmaceuticals,
`Inc. et al., No. 1:22-cv-00294 (D. Del.);
`In addition, the following litigations also involve the ’462 patent:
`
`2
`
`
`
`
`
`• Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc., No. 1:22-cv-00295
`(D. Del.) (dismissed on March 28, 2022);
`• Novo Nordisk Inc. v. Rio Biopharmaceuticals, Inc., No. 1:22-cv-00294
`(D. Del.);
`• Novo Nordisk A/S v. Sun Pharm. Indus. Ltd., No. 1:22-cv-00296 (D.
`Del.);
`• Novo Nordisk Inc. v. Zydus Worldwide DMCC, No. 1:22-cv-00297 (D.
`Del.);
`• Novo Nordisk Inc. v. Mylan Pharms. Inc., No. 22-cv-01040-CFC (D.
`Del.)
`• Novo Nordisk Inc. v. Dr. Reddy’s Laby’s Ltd., No. 1:22-cv-00298 (D.
`Del.); and
`• Novo Nordisk Inc. v. Alvogen, Inc., No. 1:22-cv-00299 (D. Del.).
`Petitioner is not aware of any other pending litigation, or any pending
`
`proceedings in front of the Patent Trial and Appeal Board except for Mylan
`
`Pharmaceuticals Inc. v. Novo Nordisk A/S, Case No. IPR2023-00724 and Dr.
`
`Reddy’s Laboratories, Inc. and Dr. Reddy’s Laboratories, Ltd. v. Novo Nordisk A/S,
`
`Case No. IPR2024-00009.
`
`C.
`
`Identification of Counsel (37 C.F.R. § 42.8(b)(3))
`Lead Counsel
`Back-Up Counsel
`Christopher B. Ferenc
`Brian Sodikoff
`Reg No. 59,365
`Reg No. 54,697
`Katten Muchin Rosenman LLP
`Katten Muchin Rosenman LLP
`1919 Pennsylvania Ave., N.W.
`525 West Monroe Street
`Suite 800
`Chicago, IL 60661
`Washington, DC 20006
`Phone: (312) 902-5200
`Phone: (202) 625-3500
`Email: brian.sodikoff@katten.com
`Email: christopher.ferenc@katten.com
`
`3
`
`
`
`
`
`
`
`D.
`Service Information (37 C.F.R. § 42.8(b)(4))
`Petitioner respectfully requests all correspondence be directed to lead counsel
`
`and back-up counsel at the contact information provided above.
`
`
`
`Respectfully submitted,
`
`Dated: November 21, 2023
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` By: /Brian Sodikoff/
`Brian Sodikoff
`Reg No. 54,697
`KATTEN MUCHIN ROSENMAN LLP
`525 West Monroe Street
`Chicago, IL 60661
`
` Counsel for Petitioner
`Sun Pharmaceutical Industries Ltd. and
`Sun Pharmaceuticals Industries, Inc.
`
`
`
`
`
`
`
`
`
`
`
`4
`
`
`
`
`
`CERTIFICATE OF SERVICE
`The undersigned certifies that the foregoing Petitioner’s Updated Mandatory
`
`Notice under 37 C.F.R. 42 were served on Patent Owner as follows:
`
`J. Steven Baughman - steve.baughman@groombridgewu.com
`Megan Raymond - megan.raymond@groombridgewu.com
`Novo-Semaglutide-IPR@groombridgewu.com
`
`
`Dated: November 21, 2023
`
`
`
`
`
`
`
`
`
`
`
`By: /Brian Sodikoff/
`Brian Sodikoff
`Reg No. 54,697
`KATTEN MUCHIN ROSENMAN LLP
`525 West Monroe Street
`Chicago, IL 60661
`
`Counsel for Petitioner
`Sun Pharmaceutical Industries Ltd. and
`Sun Pharmaceuticals Industries, Inc.
`
`5
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
